Novo Nordisk Shares Slide: Uncertainty Surrounds CagriSema Trial Results

Novo Nordisk’s stock plummets after mixed CagriSema trial results raise doubts about the drug’s efficacy in obesity treatment. Investors question its competitive edge, while analysts debate the long-term impact. The coming months will be crucial for the pharmaceutical giant to restore market confidence.

Breaking Barriers: FTC’s Historic Move to Reshape Advertising Industry Under Trump Administration

The FTC, under Trump’s administration, has approved a $13.5 billion merger to transform the advertising industry. This landmark deal aims to end biased coordination, promote fairness, and foster competition, potentially benefiting smaller media outlets and reshaping market dynamics.